000105.KS
Yuhan Corporation [000105.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000105.KS Stock Summary
Top 10 Correlated ETFs
000105.KS
Top 10 Correlated Stocks
000105.KS
In the News
000105.KS Financial details
Company Rating
Buy
Market Cap
5288.93B
Income
143.16B
Revenue
1858.98B
Book val./share
27455.34
Cash/share
-
Dividend
-
Dividend %
-
Employees
2K
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
48.99
Forward P/E
-
PEG
10.53
P/S
2.63
P/B
2.18
P/C
-
P/FCF
-56.3
Quick Ratio
-
Current Ratio
2.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.95K
EPS next Y
-
EPS next Q
-
EPS this Y
36.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.94%
Revenue last 5Y
4.66%
Revenue Q/Q
-9.5%
EPS Q/Q
342.98%
-
-
-
-
SMA20
-2.02%
SMA50
8.33%
SMA100
6.91%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
4%
ROC
0.04%
Gross Margin
30%
Oper. Margin
4%
Profit Margin
5%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
52400.0-73400.0
52W High
-17.3%
52W Low
+15.84%
RSI
40
Rel Volume
0.63
Avg Volume
2.49K
Volume
1.55K
Perf Week
-5.89%
Perf Month
0.33%
Perf Quarter
2.53%
Perf Half Y
-6.62%
-
-
-
-
Beta
0.463
-
-
Volatility
1005.29%, 1723.01%
Prev Close
-0.16%
Price
60700
Change
-3.34%
000105.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 24.91K | 24.76K | 24.62K | 24.8K | 24.8K | |
| Net income per share | 673.22 | 2.95K | 1.5K | 1.33K | 1.82K | |
| Operating cash flow per share | 1.11K | 440.65 | 1.44K | 1.39K | 1.92K | |
| Free cash flow per share | 323.95 | -952.93 | 249.77 | 71.93 | -799.4 | |
| Cash per share | 6.98K | 6.81K | 6.37K | 4.86K | 4.3K | |
| Book value per share | 27.7K | 28.12K | 28.1K | 27.73K | 27.36K | |
| Tangible book value per share | 27.28K | 27.33K | 26.96K | 26.12K | 24.43K | |
| Share holders equity per share | 27.7K | 28.12K | 28.1K | 27.73K | 27.36K | |
| Interest debt per share | 1.59K | 1.92K | 1.86K | 1.38K | 3.12K | |
| Market cap | 2466.13B | 4579.84B | 4052.22B | 3938.24B | 4700.34B | |
| Enterprise value | 2283.39B | 4349.44B | 3923.4B | 3740.58B | 4631.15B | |
| P/E ratio | 61.64 | 23.76 | 39.5 | 41.39 | 34.54 | |
| Price to sales ratio | 1.67 | 2.83 | 2.4 | 2.22 | 2.53 | |
| POCF ratio | 37.37 | 158.86 | 40.93 | 39.57 | 32.61 | |
| PFCF ratio | 128.11 | -73.46 | 236.62 | 764.61 | -78.43 | |
| P/B Ratio | 1.5 | 2.49 | 2.1 | 1.98 | 2.29 | |
| PTB ratio | 1.5 | 2.49 | 2.1 | 1.98 | 2.29 | |
| EV to sales | 1.54 | 2.69 | 2.32 | 2.11 | 2.49 | |
| Enterprise value over EBITDA | 18.57 | 22.65 | 20.36 | 25.02 | 45.69 | |
| EV to operating cash flow | 34.6 | 150.86 | 39.63 | 37.58 | 32.13 | |
| EV to free cash flow | 118.61 | -69.76 | 229.1 | 726.23 | -77.28 | |
| Earnings yield | 0.02 | 0.04 | 0.03 | 0.02 | 0.03 | |
| Free cash flow yield | 0.01 | -0.01 | 0 | 0 | -0.01 | |
| Debt to equity | 0.06 | 0.07 | 0.06 | 0.05 | 0.11 | |
| Debt to assets | 0.04 | 0.05 | 0.05 | 0.04 | 0.08 | |
| Net debt to EBITDA | -1.49 | -1.2 | -0.67 | -1.32 | -0.68 | |
| Current ratio | 3.17 | 3.13 | 2.83 | 2.74 | 2.15 | |
| Interest coverage | 20.73 | 48.76 | 47.57 | 30.7 | 9 | |
| Income quality | 1.8 | 0.15 | 1 | 1.1 | 1.06 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.57 | 0.12 | 0.24 | 0.27 | 0.2 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.09 | 0.06 | 0.06 | 0.09 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.04 | 0.06 | 0.05 | |
| Capex to operating cash flow | -0.71 | -3.16 | -0.83 | -0.95 | -1.42 | |
| Capex to revenue | -0.03 | -0.06 | -0.05 | -0.05 | -0.11 | |
| Capex to depreciation | -0.8 | -1.53 | -1.55 | -2.19 | -4.57 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 20.49K | 43.18K | 30.76K | 28.79K | 33.43K | |
| ROIC | 0.02 | 0.05 | 0.05 | 0.05 | 0.02 | |
| Return on tangible assets | 0.02 | 0.08 | 0.04 | 0.04 | 0.05 | |
| Graham Net | 7.07K | 5.96K | 6.1K | 6.02K | 2.44K | |
| Working capital | 764.72B | 813.34B | 792.12B | 754.74B | 673.27B | |
| Tangible asset value | 1621.26B | 1788B | 1848.3B | 1870.25B | 1948.37B | |
| Net current asset value | 649.74B | 648.5B | 696.17B | 723.98B | 544.12B | |
| Invested capital | 0.06 | 0.07 | 0.06 | 0.05 | 0.11 | |
| Average receivables | 446.27B | 496.28B | 491.34B | 521.63B | 561.06B | |
| Average payables | 100.39B | 116.65B | 132.06B | 137.7B | 156.45B | |
| Average inventory | 217.89B | 219.45B | 263.38B | 275B | 279.99B | |
| Days sales outstanding | 124.65 | 109.73 | 107.19 | 112.55 | 112.81 | |
| Days payables outstanding | 38.53 | 42.12 | 44.44 | 38.82 | 51.76 | |
| Days of inventory on hand | 65 | 86.65 | 86.23 | 79.87 | 82.28 | |
| Receivables turnover | 2.93 | 3.33 | 3.41 | 3.24 | 3.24 | |
| Payables turnover | 9.47 | 8.67 | 8.21 | 9.4 | 7.05 | |
| Inventory turnover | 5.62 | 4.21 | 4.23 | 4.57 | 4.44 | |
| ROE | 0.02 | 0.1 | 0.05 | 0.05 | 0.07 | |
| Capex per share | -786.46 | -1.39K | -1.19K | -1.32K | -2.72K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.3K | 6.2K | 6.94K | 6.43K | 5.83K | |
| Net income per share | 525.97 | 311.41 | 121.53 | 260.95 | 1.24K | |
| Operating cash flow per share | 389.35 | 599.25 | 193.25 | 384.62 | 0 | |
| Free cash flow per share | 40.91 | 53.25 | -368.35 | -431.37 | 0 | |
| Cash per share | 4.86K | 5K | 3.96K | 3.98K | 0 | |
| Book value per share | 27.78K | 27.6K | 27.43K | 26.37K | 27.46K | |
| Tangible book value per share | 26.16K | 25.96K | 25.68K | 24.7K | 37.52K | |
| Share holders equity per share | 27.78K | 27.6K | 27.43K | 26.37K | 27.46K | |
| Interest debt per share | 1.35K | 1.44K | 1.6K | 2.16K | 0 | |
| Market cap | 3932.14B | 3577.55B | 3920.31B | 4804.56B | 4703.65B | |
| Enterprise value | 3734.47B | 3356.95B | 3781.17B | 4691.58B | 4703.65B | |
| P/E ratio | 26.14 | 40.22 | 112.93 | 61.31 | 12.69 | |
| Price to sales ratio | 8.73 | 8.07 | 7.91 | 9.95 | 10.76 | |
| POCF ratio | 141.26 | 83.6 | 284.09 | 166.4 | 0 | |
| PFCF ratio | 1.34K | 940.85 | -149.04 | -148.37 | 0 | |
| P/B Ratio | 1.98 | 1.82 | 2 | 2.43 | 2.28 | |
| PTB ratio | 1.98 | 1.82 | 2 | 2.43 | 2.28 | |
| EV to sales | 8.29 | 7.58 | 7.63 | 9.71 | 10.76 | |
| Enterprise value over EBITDA | 202.35 | 61.9 | 24.74 | 32.47 | 787.31 | |
| EV to operating cash flow | 134.16 | 78.45 | 274.01 | 162.48 | 0 | |
| EV to free cash flow | 1.28K | 882.84 | -143.75 | -144.88 | 0 | |
| Earnings yield | 0.01 | 0.01 | 0 | 0 | 0.02 | |
| Free cash flow yield | 0 | 0 | -0.01 | -0.01 | 0 | |
| Debt to equity | 0.05 | 0.05 | 0.06 | 0.08 | 0 | |
| Debt to assets | 0.04 | 0.04 | 0.05 | 0.06 | 0 | |
| Net debt to EBITDA | -10.71 | -4.07 | -0.91 | -0.78 | 0 | |
| Current ratio | 2.74 | 2.7 | 2.7 | 2.32 | 0 | |
| Interest coverage | 6.99 | 42.32 | 23.05 | 0.39 | 0 | |
| Income quality | 0.77 | 1.92 | 1.61 | 1.52 | 0 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0 | 3.14 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.25 | 0.3 | 0 | |
| Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.07 | 0 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.06 | 0.07 | 0 | |
| Capex to operating cash flow | -0.89 | -0.91 | -2.91 | -2.12 | 0 | |
| Capex to revenue | -0.06 | -0.09 | -0.08 | -0.13 | 0 | |
| Capex to depreciation | -2.3 | -3.65 | -3.66 | -5.54 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.13K | 13.91K | 8.66K | 12.44K | 27.62K | |
| ROIC | 0.09 | 0.01 | 0.01 | 0 | 0 | |
| Return on tangible assets | 0.02 | 0.01 | 0 | 0.01 | 0.03 | |
| Graham Net | 6.03K | 5.8K | 4.76K | 3.71K | 0 | |
| Working capital | 754.74B | 758.68B | 731.81B | 702.04B | 0 | |
| Tangible asset value | 1870.25B | 1853.41B | 1833.69B | 1854.34B | 2814.9B | |
| Net current asset value | 723.98B | 710.04B | 640.83B | 596.46B | 0 | |
| Invested capital | 0.05 | 0.05 | 0.06 | 0.08 | 0 | |
| Average receivables | 547.87B | 549.41B | 573.57B | 615.17B | 317.23B | |
| Average payables | 139.58B | 153.24B | 168.58B | 185.43B | 103.21B | |
| Average inventory | 275.1B | 275.96B | 270.31B | 271.67B | 139.71B | |
| Days sales outstanding | 109.39 | 111.98 | 108.19 | 118.21 | 0 | |
| Days payables outstanding | 38.3 | 50.55 | 43.16 | 54.87 | 0 | |
| Days of inventory on hand | 78.8 | 80.99 | 69.27 | 74.28 | 0 | |
| Receivables turnover | 0.82 | 0.8 | 0.83 | 0.76 | 0 | |
| Payables turnover | 2.35 | 1.78 | 2.09 | 1.64 | 0 | |
| Inventory turnover | 1.14 | 1.11 | 1.3 | 1.21 | 0 | |
| ROE | 0.02 | 0.01 | 0 | 0.01 | 0.04 | |
| Capex per share | -348.44 | -546 | -561.6 | -815.99 | 0 |
000105.KS Frequently Asked Questions
What is Yuhan Corporation stock symbol ?
Yuhan Corporation is a KR stock and trading under the symbol 000105.KS
What is Yuhan Corporation stock quote today ?
Yuhan Corporation stock price is $60700 today.
Is Yuhan Corporation stock public?
Yes, Yuhan Corporation is a publicly traded company.
Company Profile
- Volume Average 2.49K
- Market Capitalization 5288.93B
- Employee 2K
- CEO Mr. Wook-Je Cho
- Headquarters Seoul,KR
- IPO Date 2005-09-29
-
Website
https://www.yuhan.co.kr 
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
